For Research Use Only. Not for use in diagnostic procedures

Teriparatide (rhPTH 1-34) is a recombinant human parathyroid hormone derivative consisting of the first 34 amino acids of the hormone. Teriparatide was approved as a drug by the FDA in 2002 and is sold by Eli Lilly & Co. under the brand name Forteo. Teriparatide is indicated for use in patients with osteoporosis. It is currently administered by injection and has an anabolic effect on bone, binding to the PTH/PTHrp Type 1 receptor with the same affinity as the intact molecule, PTH (1-84). This receptor activation results in a series of events leading to the formation of new trabecular and cortical bone. Research is continuing at pharmaceutical and biotech companies to pursue similar drugs and alternate delivery pathways.

Immunogenicity for this drug, defined as the presence of antibodies to human PTH (1-34), was detected in 2.8% of women receiving teriparatide during the clinical trials of Forteo. The detection of these circulating antibodies may be of clinical relevance for the proper assessment of patients.

The Anti-Human PTH (1-34) Antibody ELISA Kit is a two-step enzyme-linked immunosorbant assay (ELISA) for the qualitative detection of antibodies to human PTH (1-34) in serum, plasma, or cell culture media.

This product is made to order. For ordering information, please contact your sales repesentative or customer service.